25 XP   0   0   10

GLENMARK PHARMACEUTICALS LTD.
Buy, Hold or Sell?

Let's analyse GLENMARK PHARMACEUTICALS LTD. together

PenkeI guess you are interested in GLENMARK PHARMACEUTICALS LTD.. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of GLENMARK PHARMACEUTICALS LTD.. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about GLENMARK PHARMACEUTICALS LTD.

I send you an email if I find something interesting about GLENMARK PHARMACEUTICALS LTD..

Quick analysis of GLENMARK PHARMACEUTICALS LTD. (30 sec.)










What can you expect buying and holding a share of GLENMARK PHARMACEUTICALS LTD.? (30 sec.)

How much money do you get?

How much money do you get?
INR0.23
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
INR335.73
Expected worth in 1 year
INR390.63
How sure are you?
100.0%

+ What do you gain per year?

Total Gains per Share
INR74.26
Return On Investment
6.9%

For what price can you sell your share?

Current Price per Share
INR1,079.55
Expected price per share
INR883.50 - INR
How sure are you?
50%

1. Valuation of GLENMARK PHARMACEUTICALS LTD. (5 min.)




Live pricePrice per Share (EOD)

INR1,079.55

Intrinsic Value Per Share

INR-133.38 - INR-111.15

Total Value Per Share

INR202.35 - INR224.58

2. Growth of GLENMARK PHARMACEUTICALS LTD. (5 min.)




Is GLENMARK PHARMACEUTICALS LTD. growing?

Current yearPrevious yearGrowGrow %
How rich?$1.1b$1b$46.4m4.1%

How much money is GLENMARK PHARMACEUTICALS LTD. making?

Current yearPrevious yearGrowGrow %
Making money$35.6m$113m-$77.3m-216.8%
Net Profit Margin2.6%7.7%--

How much money comes from the company's main activities?

3. Financial Health of GLENMARK PHARMACEUTICALS LTD. (5 min.)




What can you expect buying and holding a share of GLENMARK PHARMACEUTICALS LTD.? (5 min.)

Welcome investor! GLENMARK PHARMACEUTICALS LTD.'s management wants to use your money to grow the business. In return you get a share of GLENMARK PHARMACEUTICALS LTD..

What can you expect buying and holding a share of GLENMARK PHARMACEUTICALS LTD.?

First you should know what it really means to hold a share of GLENMARK PHARMACEUTICALS LTD.. And how you can make/lose money.

Speculation

The Price per Share of GLENMARK PHARMACEUTICALS LTD. is INR1,080. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of GLENMARK PHARMACEUTICALS LTD..
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in GLENMARK PHARMACEUTICALS LTD., you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is INR335.73. Based on the TTM, the Book Value Change Per Share is INR13.72 per quarter. Based on the YOY, the Book Value Change Per Share is INR71.66 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is INR4.84 per quarter.
Based on historical numbers we can estimate the returns while holding a share of GLENMARK PHARMACEUTICALS LTD..

How much money are you going to get?

 MRQTTMYOY5Y10Y
 INR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per Share
Usd Eps0.130.0%0.130.0%0.400.0%0.330.0%0.310.0%
Usd Book Value Change Per Share0.160.0%0.160.0%0.860.1%0.330.0%0.400.0%
Usd Dividend Per Share0.060.0%0.060.0%0.040.0%0.040.0%0.030.0%
Usd Total Gains Per Share0.220.0%0.220.0%0.900.1%0.370.0%0.440.0%
Usd Price Per Share5.58-5.58-5.31-5.34-6.91-
Price to Earnings Ratio44.14-44.14-13.25-19.62-25.11-
Price-to-Total Gains Ratio25.05-25.05-5.90-54.20-67.73-
Price to Book Ratio1.39-1.39-1.37-1.76-3.44-
Price-to-Total Gains Ratio25.05-25.05-5.90-54.20-67.73-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share12.9546
Number of shares77
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.060.04
Usd Book Value Change Per Share0.160.33
Usd Total Gains Per Share0.220.37
Gains per Quarter (77 shares)17.1528.30
Gains per Year (77 shares)68.62113.19
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
118515911102103
23610112823204216
35415219734305329
47220326646407442
58925433557509555
610730440469611668
712535547380712781
814340654291814894
91614576111039161007
1017950768011410181120

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%10.00.00.0100.0%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%10.00.00.0100.0%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%10.00.00.0100.0%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%10.00.00.0100.0%

Fundamentals of GLENMARK PHARMACEUTICALS LTD.

About GLENMARK PHARMACEUTICALS LTD.

Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, Japan, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, and oncology; and various active pharmaceutical ingredients. Its product pipeline includes ISB 2001, a BCMA x CD38 x CD3 trispecific antibody, which is in Phase 1 clinical trial for oncology; GRC 39815, a retinoid-related orphan receptor gamma t inverse agonist, which is in Phase 1 clinical trial for the treatment of chronic obstructive pulmonary disease; and GRC 54276, a hematopoietic progenitor kinase 1 inhibitor, which is in Phase 1 clinical trial for the treatment of solid tumors. Its pipeline also comprises ISB 1342, CD38 X CD3 bispecific antibody, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma; ISB 1442, a CD38 x CD47 immune cell engager, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma; ISB 880, a IL-1RAP antibody, which is in Phase 1 clinical trial for the treatment of autoimmune diseases; and ISB 830, a OX40 antagonist, which is in Phase 2 clinical trial for the treatment of atopic dermatitis. In addition, the company offers Ryaltris nasal spray for the treatment of seasonal allergic rhinitis. Glenmark Pharmaceuticals Limited was incorporated in 1977 and is based in Mumbai, India.

Fundamental data was last updated by Penke on 2024-04-05 04:02:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of GLENMARK PHARMACEUTICALS LTD..

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit GLENMARK PHARMACEUTICALS LTD. earns for each ₹1 of revenue.

  • Above 10% is considered healthy but always compare GLENMARK PHARMACEUTICALS LTD. to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 2.6% means that ₹0.03 for each ₹1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of GLENMARK PHARMACEUTICALS LTD.:

  • The MRQ is 2.6%. The company is making a profit. +1
  • The TTM is 2.6%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ2.6%TTM2.6%0.0%
TTM2.6%YOY7.7%-5.1%
TTM2.6%5Y7.2%-4.6%
5Y7.2%10Y8.0%-0.8%
1.1.2. Return on Assets

Shows how efficient GLENMARK PHARMACEUTICALS LTD. is using its assets to generate profit.

  • Above 5% is considered healthy but always compare GLENMARK PHARMACEUTICALS LTD. to the Drug Manufacturers - Specialty & Generic industry mean.
  • 1.5% Return on Assets means that GLENMARK PHARMACEUTICALS LTD. generated ₹0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of GLENMARK PHARMACEUTICALS LTD.:

  • The MRQ is 1.5%. Using its assets, the company is less efficient in making profit.
  • The TTM is 1.5%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ1.5%TTM1.5%0.0%
TTM1.5%YOY5.5%-4.0%
TTM1.5%5Y5.1%-3.6%
5Y5.1%10Y5.7%-0.6%
1.1.3. Return on Equity

Shows how efficient GLENMARK PHARMACEUTICALS LTD. is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare GLENMARK PHARMACEUTICALS LTD. to the Drug Manufacturers - Specialty & Generic industry mean.
  • 3.1% Return on Equity means GLENMARK PHARMACEUTICALS LTD. generated ₹0.03 for each ₹1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of GLENMARK PHARMACEUTICALS LTD.:

  • The MRQ is 3.1%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 3.1%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ3.1%TTM3.1%0.0%
TTM3.1%YOY10.4%-7.2%
TTM3.1%5Y11.3%-8.2%
5Y11.3%10Y13.9%-2.6%

1.2. Operating Efficiency of GLENMARK PHARMACEUTICALS LTD..

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient GLENMARK PHARMACEUTICALS LTD. is operating .

  • Measures how much profit GLENMARK PHARMACEUTICALS LTD. makes for each ₹1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare GLENMARK PHARMACEUTICALS LTD. to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated ₹0.00  for each ₹1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of GLENMARK PHARMACEUTICALS LTD.:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY15.0%-15.0%
TTM-5Y11.1%-11.1%
5Y11.1%10Y13.2%-2.1%
1.2.2. Operating Ratio

Measures how efficient GLENMARK PHARMACEUTICALS LTD. is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.32 means that the operating costs are ₹1.32 for each ₹1 in net sales.

Let's take a look of the Operating Ratio trends of GLENMARK PHARMACEUTICALS LTD.:

  • The MRQ is 1.322. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.322. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.322TTM1.3220.000
TTM1.322YOY1.244+0.078
TTM1.3225Y1.264+0.058
5Y1.26410Y1.225+0.039

1.3. Liquidity of GLENMARK PHARMACEUTICALS LTD..

1.3. Liquidity
1.3.1. Current Ratio

Measures if GLENMARK PHARMACEUTICALS LTD. is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.85 means the company has ₹1.85 in assets for each ₹1 in short-term debts.

Let's take a look of the Current Ratio trends of GLENMARK PHARMACEUTICALS LTD.:

  • The MRQ is 1.853. The company is able to pay all its short-term debts. +1
  • The TTM is 1.853. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.853TTM1.8530.000
TTM1.853YOY1.766+0.087
TTM1.8535Y1.737+0.116
5Y1.73710Y1.788-0.051
1.3.2. Quick Ratio

Measures if GLENMARK PHARMACEUTICALS LTD. is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare GLENMARK PHARMACEUTICALS LTD. to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 1.21 means the company can pay off ₹1.21 for each ₹1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of GLENMARK PHARMACEUTICALS LTD.:

  • The MRQ is 1.214. The company is just able to pay all its short-term debts with the most liquid assets.
  • The TTM is 1.214. The company is just able to pay all its short-term debts with the most liquid assets.
Trends
Current periodCompared to+/- 
MRQ1.214TTM1.2140.000
TTM1.214YOY0.969+0.245
TTM1.2145Y0.988+0.226
5Y0.98810Y1.016-0.028

1.4. Solvency of GLENMARK PHARMACEUTICALS LTD..

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of GLENMARK PHARMACEUTICALS LTD. assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare GLENMARK PHARMACEUTICALS LTD. to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.51 means that GLENMARK PHARMACEUTICALS LTD. assets are financed with 51.1% credit (debt) and the remaining percentage (100% - 51.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of GLENMARK PHARMACEUTICALS LTD.:

  • The MRQ is 0.511. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.511. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.511TTM0.5110.000
TTM0.511YOY0.468+0.043
TTM0.5115Y0.538-0.027
5Y0.53810Y0.581-0.042
1.4.2. Debt to Equity Ratio

Measures if GLENMARK PHARMACEUTICALS LTD. is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare GLENMARK PHARMACEUTICALS LTD. to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 104.5% means that company has ₹1.04 debt for each ₹1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of GLENMARK PHARMACEUTICALS LTD.:

  • The MRQ is 1.045. The company is able to pay all its debts with equity. +1
  • The TTM is 1.045. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.045TTM1.0450.000
TTM1.045YOY0.880+0.165
TTM1.0455Y1.185-0.140
5Y1.18510Y1.438-0.253

2. Market Valuation of GLENMARK PHARMACEUTICALS LTD.

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₹1 in earnings GLENMARK PHARMACEUTICALS LTD. generates.

  • Above 15 is considered overpriced but always compare GLENMARK PHARMACEUTICALS LTD. to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 44.14 means the investor is paying ₹44.14 for every ₹1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of GLENMARK PHARMACEUTICALS LTD.:

  • The EOD is 102.487. Based on the earnings, the company is expensive. -2
  • The MRQ is 44.145. Based on the earnings, the company is overpriced. -1
  • The TTM is 44.145. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD102.487MRQ44.145+58.342
MRQ44.145TTM44.1450.000
TTM44.145YOY13.251+30.894
TTM44.1455Y19.619+24.525
5Y19.61910Y25.106-5.487
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of GLENMARK PHARMACEUTICALS LTD.:

  • The EOD is 1,728.039. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is 744.327. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 744.327. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD1,728.039MRQ744.327+983.712
MRQ744.327TTM744.3270.000
TTM744.327YOY39.174+705.153
TTM744.3275Y208.455+535.872
5Y208.45510Y43.929+164.526
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of GLENMARK PHARMACEUTICALS LTD. is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 1.39 means the investor is paying ₹1.39 for each ₹1 in book value.

Let's take a look of the Price to Book Ratio trends of GLENMARK PHARMACEUTICALS LTD.:

  • The EOD is 3.216. Based on the equity, the company is fair priced.
  • The MRQ is 1.385. Based on the equity, the company is underpriced. +1
  • The TTM is 1.385. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD3.216MRQ1.385+1.830
MRQ1.385TTM1.3850.000
TTM1.385YOY1.373+0.012
TTM1.3855Y1.764-0.379
5Y1.76410Y3.435-1.671
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of GLENMARK PHARMACEUTICALS LTD. compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--13.72413.7240%71.655-81%27.534-50%33.573-59%
Book Value Per Share--335.731335.7310%322.007+4%264.369+27%205.878+63%
Current Ratio--1.8531.8530%1.766+5%1.737+7%1.788+4%
Debt To Asset Ratio--0.5110.5110%0.468+9%0.538-5%0.581-12%
Debt To Equity Ratio--1.0451.0450%0.880+19%1.185-12%1.438-27%
Dividend Per Share--4.8414.8410%3.285+47%3.091+57%2.716+78%
Eps--10.53410.5340%33.372-68%27.712-62%26.045-60%
Free Cash Flow Per Share--0.6250.6250%11.288-94%8.793-93%5.748-89%
Free Cash Flow To Equity Per Share---2.120-2.1200%-7.157+238%-6.963+228%0.969-319%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---111.152--------
Intrinsic Value_10Y_min---133.384--------
Intrinsic Value_1Y_max--4.506--------
Intrinsic Value_1Y_min--2.777--------
Intrinsic Value_3Y_max--1.616--------
Intrinsic Value_3Y_min---5.588--------
Intrinsic Value_5Y_max---15.648--------
Intrinsic Value_5Y_min---29.159--------
Market Cap304636055400.000+57%131217420000.000131217420000.0000%124783533600.000+5%125480537960.000+5%162383673660.000-19%
Net Profit Margin--0.0260.0260%0.077-66%0.072-64%0.080-68%
Operating Margin----0%0.150-100%0.111-100%0.132-100%
Operating Ratio--1.3221.3220%1.244+6%1.264+5%1.225+8%
Pb Ratio3.216+57%1.3851.3850%1.373+1%1.764-21%3.435-60%
Pe Ratio102.487+57%44.14544.1450%13.251+233%19.619+125%25.106+76%
Price Per Share1079.550+57%465.000465.0000%442.200+5%444.670+5%575.445-19%
Price To Free Cash Flow Ratio1728.039+57%744.327744.3270%39.174+1800%208.455+257%43.929+1594%
Price To Total Gains Ratio58.150+57%25.04725.0470%5.901+324%54.198-54%67.731-63%
Quick Ratio--1.2141.2140%0.969+25%0.988+23%1.016+19%
Return On Assets--0.0150.0150%0.055-72%0.051-70%0.057-73%
Return On Equity--0.0310.0310%0.104-70%0.113-72%0.139-77%
Total Gains Per Share--18.56518.5650%74.940-75%30.625-39%36.289-49%
Usd Book Value--1136870760.0001136870760.0000%1090397640.000+4%895221264.000+27%697155876.000+63%
Usd Book Value Change Per Share--0.1650.1650%0.860-81%0.330-50%0.403-59%
Usd Book Value Per Share--4.0294.0290%3.864+4%3.172+27%2.471+63%
Usd Dividend Per Share--0.0580.0580%0.039+47%0.037+57%0.033+78%
Usd Eps--0.1260.1260%0.400-68%0.333-62%0.313-60%
Usd Free Cash Flow--2115480.0002115480.0000%38224200.000-94%29775816.000-93%19464624.000-89%
Usd Free Cash Flow Per Share--0.0070.0070%0.135-94%0.106-93%0.069-89%
Usd Free Cash Flow To Equity Per Share---0.025-0.0250%-0.086+238%-0.084+228%0.012-319%
Usd Market Cap3655632664.800+57%1574609040.0001574609040.0000%1497402403.200+5%1505766455.520+5%1948604083.920-19%
Usd Price Per Share12.955+57%5.5805.5800%5.306+5%5.336+5%6.905-19%
Usd Profit--35669400.00035669400.0000%113005320.000-68%93840096.000-62%87838140.000-59%
Usd Revenue--1389988200.0001389988200.0000%1476588360.000-6%1328124096.000+5%1125334344.000+24%
Usd Total Gains Per Share--0.2230.2230%0.899-75%0.368-39%0.435-49%
 EOD+4 -4MRQTTM+0 -0YOY+13 -225Y+16 -1910Y+12 -23

3.2. Fundamental Score

Let's check the fundamental score of GLENMARK PHARMACEUTICALS LTD. based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15102.487
Price to Book Ratio (EOD)Between0-13.216
Net Profit Margin (MRQ)Greater than00.026
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.214
Current Ratio (MRQ)Greater than11.853
Debt to Asset Ratio (MRQ)Less than10.511
Debt to Equity Ratio (MRQ)Less than11.045
Return on Equity (MRQ)Greater than0.150.031
Return on Assets (MRQ)Greater than0.050.015
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of GLENMARK PHARMACEUTICALS LTD. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5069.787
Ma 20Greater thanMa 501,021.733
Ma 50Greater thanMa 100951.543
Ma 100Greater thanMa 200903.200
OpenGreater thanClose1,073.200
Total4/5 (80.0%)



Latest Balance Sheet

Balance Sheet of 2023-03-31. Currency in INR. All numbers in thousands.

Summary
Total Assets193,716,760
Total Liabilities98,977,530
Total Stockholder Equity94,739,230
 As reported
Total Liabilities 98,977,530
Total Stockholder Equity+ 94,739,230
Total Assets = 193,716,760

Assets

Total Assets193,716,760
Total Current Assets84,236,370
Long-term Assets94,979,570
Total Current Assets
Cash And Cash Equivalents 11,592,030
Short-term Investments 1,299,970
Net Receivables 40,986,060
Inventory 23,736,200
Other Current Assets 4,717,290
Total Current Assets  (as reported)84,236,370
Total Current Assets  (calculated)82,331,550
+/- 1,904,820
Long-term Assets
Property Plant Equipment 50,193,410
Goodwill 736,190
Intangible Assets 23,426,820
Other Assets 19,969,600
Long-term Assets  (as reported)94,979,570
Long-term Assets  (calculated)94,326,020
+/- 653,550

Liabilities & Shareholders' Equity

Total Current Liabilities45,462,420
Long-term Liabilities44,868,870
Total Stockholder Equity94,739,230
Total Current Liabilities
Short Long Term Debt 4,955,820
Accounts payable 23,918,610
Other Current Liabilities 5,465,310
Total Current Liabilities  (as reported)45,462,420
Total Current Liabilities  (calculated)34,339,740
+/- 11,122,680
Long-term Liabilities
Long term Debt Total 40,292,600
Capital Lease Obligations Min Short Term Debt2,795,180
Long-term Liabilities Other 13,290
Long-term Liabilities  (as reported)44,868,870
Long-term Liabilities  (calculated)43,101,070
+/- 1,767,800
Total Stockholder Equity
Common Stock282,170
Retained Earnings 96,025,520
Capital Surplus 16,853,600
Other Stockholders Equity -18,422,060
Total Stockholder Equity (as reported)94,739,230
Total Stockholder Equity (calculated)94,739,230
+/-0
Other
Capital Stock282,170
Cash and Short Term Investments 12,892,000
Common Stock Shares Outstanding 282,168
Liabilities and Stockholders Equity 193,716,760
Net Debt 29,046,940
Net Invested Capital 138,216,430
Net Working Capital 48,281,890
Property Plant and Equipment Gross 50,193,410



Balance Sheet

Currency in INR. All numbers in thousands.

 Trend2023-03-312022-03-312021-03-312020-03-312019-03-312018-03-312017-03-312016-03-312015-03-312014-03-31
> Total Assets 
86,336,030
96,875,060
108,359,950
122,119,710
130,209,550
132,956,470
146,848,070
156,035,770
170,832,880
193,716,760
193,716,760170,832,880156,035,770146,848,070132,956,470130,209,550122,119,710108,359,95096,875,06086,336,030
   > Total Current Assets 
47,626,940
53,232,740
59,061,420
68,746,390
69,886,920
66,968,250
68,036,160
73,595,790
82,823,480
84,236,370
84,236,37082,823,48073,595,79068,036,16066,968,25069,886,92068,746,39059,061,42053,232,74047,626,940
       Cash And Cash Equivalents 
7,947,990
7,637,350
8,571,210
10,563,640
12,333,560
9,362,780
11,102,750
11,380,950
14,105,260
11,592,030
11,592,03014,105,26011,380,95011,102,7509,362,78012,333,56010,563,6408,571,2107,637,3507,947,990
       Short-term Investments 
148,150
107,680
0
0
1,792,460
1,968,720
696,560
763,990
328,750
1,299,970
1,299,970328,750763,990696,5601,968,7201,792,46000107,680148,150
       Net Receivables 
22,586,780
27,324,270
24,926,460
30,562,960
30,431,590
28,279,110
24,089,620
25,720,550
31,011,350
40,986,060
40,986,06031,011,35025,720,55024,089,62028,279,11030,431,59030,562,96024,926,46027,324,27022,586,780
       Inventory 
9,328,790
12,690,390
17,993,130
21,390,500
20,305,850
22,520,740
21,356,240
22,768,330
24,998,330
23,736,200
23,736,20024,998,33022,768,33021,356,24022,520,74020,305,85021,390,50017,993,13012,690,3909,328,790
       Other Current Assets 
7,615,230
2,235,190
158,410
5,902,200
5,821,660
4,797,810
5,372,630
6,637,850
4,876,450
4,717,290
4,717,2904,876,4506,637,8505,372,6304,797,8105,821,6605,902,200158,4102,235,1907,615,230
   > Long-term Assets 
0
0
0
53,373,330
60,322,630
69,820,130
78,811,910
82,439,980
88,009,400
94,979,570
94,979,57088,009,40082,439,98078,811,91069,820,13060,322,63053,373,330000
       Property Plant Equipment 
17,628,130
20,569,490
24,622,860
27,451,480
28,891,500
33,321,800
40,929,010
42,035,420
46,535,500
50,193,410
50,193,41046,535,50042,035,42040,929,01033,321,80028,891,50027,451,48024,622,86020,569,49017,628,130
       Goodwill 
602,040
579,700
574,800
478,920
521,040
547,350
528,990
580,110
600,190
736,190
736,190600,190580,110528,990547,350521,040478,920574,800579,700602,040
       Long Term Investments 
183,660
171,180
281,630
243,330
0
0
0
0
0
0
000000243,330281,630171,180183,660
       Intangible Assets 
12,728,760
12,134,930
14,452,420
12,855,810
14,581,790
16,822,770
21,291,980
22,769,380
22,253,790
23,426,820
23,426,82022,253,79022,769,38021,291,98016,822,77014,581,79012,855,81014,452,42012,134,93012,728,760
       Long-term Assets Other 
0
0
0
1,280
5,630
5,920
320
1,100,220
-15,953,360
1,538,570
1,538,570-15,953,3601,100,2203205,9205,6301,280000
> Total Liabilities 
56,370,430
66,873,570
65,657,490
72,725,430
74,319,010
76,904,630
86,143,020
85,389,500
79,966,410
98,977,530
98,977,53079,966,41085,389,50086,143,02076,904,63074,319,01072,725,43065,657,49066,873,57056,370,430
   > Total Current Liabilities 
29,491,660
37,112,900
40,017,630
27,038,840
32,878,930
40,210,940
41,259,830
42,010,200
46,894,310
45,462,420
45,462,42046,894,31042,010,20041,259,83040,210,94032,878,93027,038,84040,017,63037,112,90029,491,660
       Short-term Debt 
32,669,720
37,999,320
7,874,180
1,871,890
2,950,440
3,030,240
4,425,970
5,130,150
3,700,000
0
03,700,0005,130,1504,425,9703,030,2402,950,4401,871,8907,874,18037,999,32032,669,720
       Short Long Term Debt 
32,669,720
37,999,320
39,881,060
47,236,580
4,976,070
8,749,140
8,256,400
7,986,120
10,986,050
4,955,820
4,955,82010,986,0507,986,1208,256,4008,749,1404,976,07047,236,58039,881,06037,999,32032,669,720
       Accounts payable 
13,625,840
20,456,670
19,407,930
17,432,310
18,697,840
22,207,510
21,258,430
22,377,680
22,886,620
23,918,610
23,918,61022,886,62022,377,68021,258,43022,207,51018,697,84017,432,31019,407,93020,456,67013,625,840
       Other Current Liabilities 
5,899,580
1,588,020
2,391,310
3,655,060
4,457,810
4,049,110
4,800,470
4,557,700
4,936,640
5,465,310
5,465,3104,936,6404,557,7004,800,4704,049,1104,457,8103,655,0602,391,3101,588,0205,899,580
   > Long-term Liabilities 
0
0
0
45,690,820
41,443,780
36,628,900
44,887,110
43,382,840
29,557,370
44,868,870
44,868,87029,557,37043,382,84044,887,11036,628,90041,443,78045,690,820000
       Long term Debt Total 
0
0
24,872,970
45,363,390
41,417,780
35,737,540
42,743,370
41,128,510
27,717,380
40,292,600
40,292,60027,717,38041,128,51042,743,37035,737,54041,417,78045,363,39024,872,97000
       Capital Lease Obligations 
0
0
0
0
0
0
3,173,400
2,982,890
2,916,720
2,795,180
2,795,1802,916,7202,982,8903,173,400000000
       Long-term Liabilities Other 
0
0
0
303,380
-10
6,300
4,680
6,920
311,870
13,290
13,290311,8706,9204,6806,300-10303,380000
> Total Stockholder Equity
29,832,800
30,003,360
42,702,460
49,394,280
55,890,540
56,051,840
60,705,050
70,646,270
90,866,470
94,739,230
94,739,23090,866,47070,646,27060,705,05056,051,84055,890,54049,394,28042,702,46030,003,36029,832,800
   Common Stock
271,220
271,290
282,160
282,170
282,170
282,170
282,170
282,170
282,170
282,170
282,170282,170282,170282,170282,170282,170282,170282,160271,290271,220
   Retained Earnings 
27,196,980
30,927,870
37,586,930
46,020,400
49,248,720
57,604,790
64,751,910
73,791,310
93,564,200
96,025,520
96,025,52093,564,20073,791,31064,751,91057,604,79049,248,72046,020,40037,586,93030,927,87027,196,980
   Accumulated Other Comprehensive Income 0000000000
   Capital Surplus 
0
0
17,293,470
17,296,100
17,296,100
16,853,600
16,853,600
16,853,600
16,853,600
16,853,600
16,853,60016,853,60016,853,60016,853,60016,853,60017,296,10017,296,10017,293,47000
   Treasury Stock0000000000



Balance Sheet

Currency in INR. All numbers in thousands.




Cash Flow

Currency in INR. All numbers in thousands.




Income Statement

Currency in INR. All numbers in thousands.


Latest Income Statement (annual, 2023-03-31)

Gross Profit (+$)
totalRevenue115,832,350
Cost of Revenue-42,575,360
Gross Profit73,256,99073,256,990
 
Operating Income (+$)
Gross Profit73,256,990
Operating Expense-110,583,310
Operating Income2,999,770-37,326,320
 
Operating Expense (+$)
Research Development0
Selling General Administrative26,007,760
Selling And Marketing Expenses0
Operating Expense110,583,31026,007,760
 
Net Interest Income (+$)
Interest Income3,490,360
Interest Expense-3,495,830
Other Finance Cost-3,490,360
Net Interest Income-3,495,830
 
Pretax Income (+$)
Operating Income2,999,770
Net Interest Income-3,495,830
Other Non-Operating Income Expenses0
Income Before Tax (EBT)2,398,4202,999,770
EBIT - interestExpense = -3,495,830
2,972,450
6,468,280
Interest Expense3,495,830
Earnings Before Interest and Taxes (EBIT)05,894,250
Earnings Before Interest and Taxes (EBITDA)18,293,020
 
After tax Income (+$)
Income Before Tax2,398,420
Tax Provision-3,294,030
Net Income From Continuing Ops3,774,000-895,610
Net Income2,972,450
Net Income Applicable To Common Shares2,972,450
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items4,669,610
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses26,234,960
Total Other Income/Expenses Net03,495,830
 

Technical Analysis of GLENMARK PHARMACEUTICALS LTD.
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of GLENMARK PHARMACEUTICALS LTD.. The general trend of GLENMARK PHARMACEUTICALS LTD. is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine GLENMARK PHARMACEUTICALS LTD.'s overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of GLENMARK PHARMACEUTICALS LTD..

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: .

The bearish price targets are: 1,068 > 974.05 > 883.50.

Tweet this
GLENMARK PHARMACEUTICALS LTD. Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of GLENMARK PHARMACEUTICALS LTD.. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

GLENMARK PHARMACEUTICALS LTD. Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of GLENMARK PHARMACEUTICALS LTD.. The current macd is 31.82.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the GLENMARK PHARMACEUTICALS LTD. price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for GLENMARK PHARMACEUTICALS LTD.. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the GLENMARK PHARMACEUTICALS LTD. price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
GLENMARK PHARMACEUTICALS LTD. Daily Moving Average Convergence/Divergence (MACD) ChartGLENMARK PHARMACEUTICALS LTD. Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of GLENMARK PHARMACEUTICALS LTD.. The current adx is 27.53.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy GLENMARK PHARMACEUTICALS LTD. shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
GLENMARK PHARMACEUTICALS LTD. Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of GLENMARK PHARMACEUTICALS LTD.. The current sar is 1,018.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
GLENMARK PHARMACEUTICALS LTD. Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of GLENMARK PHARMACEUTICALS LTD.. The current rsi is 69.79. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
GLENMARK PHARMACEUTICALS LTD. Daily Relative Strength Index (RSI) ChartGLENMARK PHARMACEUTICALS LTD. Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of GLENMARK PHARMACEUTICALS LTD.. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 5/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the GLENMARK PHARMACEUTICALS LTD. price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
GLENMARK PHARMACEUTICALS LTD. Daily Stochastic Oscillator ChartGLENMARK PHARMACEUTICALS LTD. Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of GLENMARK PHARMACEUTICALS LTD.. The current cci is 128.01.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
GLENMARK PHARMACEUTICALS LTD. Daily Commodity Channel Index (CCI) ChartGLENMARK PHARMACEUTICALS LTD. Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of GLENMARK PHARMACEUTICALS LTD.. The current cmo is 43.49.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
GLENMARK PHARMACEUTICALS LTD. Daily Chande Momentum Oscillator (CMO) ChartGLENMARK PHARMACEUTICALS LTD. Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of GLENMARK PHARMACEUTICALS LTD.. The current willr is -15.6264888.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
GLENMARK PHARMACEUTICALS LTD. Daily Williams %R ChartGLENMARK PHARMACEUTICALS LTD. Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of GLENMARK PHARMACEUTICALS LTD..

GLENMARK PHARMACEUTICALS LTD. Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of GLENMARK PHARMACEUTICALS LTD.. The current atr is 27.89.

GLENMARK PHARMACEUTICALS LTD. Daily Average True Range (ATR) ChartGLENMARK PHARMACEUTICALS LTD. Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of GLENMARK PHARMACEUTICALS LTD.. The current obv is 7,522,720.

GLENMARK PHARMACEUTICALS LTD. Daily On-Balance Volume (OBV) ChartGLENMARK PHARMACEUTICALS LTD. Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of GLENMARK PHARMACEUTICALS LTD.. The current mfi is 63.01.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
GLENMARK PHARMACEUTICALS LTD. Daily Money Flow Index (MFI) ChartGLENMARK PHARMACEUTICALS LTD. Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for GLENMARK PHARMACEUTICALS LTD..

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-01CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-12STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-20CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-30CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-31SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-07CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-08CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-09SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-14STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-15RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-21MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-21CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-01STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-04-04MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-15MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-24SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside

6.3. Candlestick Patterns

GLENMARK PHARMACEUTICALS LTD. Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of GLENMARK PHARMACEUTICALS LTD. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5069.787
Ma 20Greater thanMa 501,021.733
Ma 50Greater thanMa 100951.543
Ma 100Greater thanMa 200903.200
OpenGreater thanClose1,073.200
Total4/5 (80.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of GLENMARK PHARMACEUTICALS LTD. with someone you think should read this too:
  • Are you bullish or bearish on GLENMARK PHARMACEUTICALS LTD.? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about GLENMARK PHARMACEUTICALS LTD.? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about GLENMARK PHARMACEUTICALS LTD.

I send you an email if I find something interesting about GLENMARK PHARMACEUTICALS LTD..


Comments

How you think about this?

Leave a comment

Stay informed about GLENMARK PHARMACEUTICALS LTD..

Receive notifications about GLENMARK PHARMACEUTICALS LTD. in your mailbox!